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Introduction {#sec005}
============

Breast cancer has become a worldwide public health problem. In China, breast cancer is the most common tumor for women, and 169 thousand females were diagnosed with breast cancer every year \[[@pone.0157791.ref001]\]. Meanwhile, about 45 thousand females died of breast cancer \[[@pone.0157791.ref001]\]. In 2010, American Diabetes Association (ADA) and the American Cancer Society (ACS) jointly agreed that diabetic patients had a higher risk of getting breast cancer \[[@pone.0157791.ref002]\]. Moreover, diabetes is one of the most common comorbidities of breast cancer, and around 18% of breast cancer patients have diabetes \[[@pone.0157791.ref003], [@pone.0157791.ref004]\], even though 30% of them are not diagnosed \[[@pone.0157791.ref005]\]. Diabetes can increase the breast cancer morbidity by 5%\~20%, especially among younger patients. For instance, the relative risk (RR) is 1.37 for patients aged between 55--64 and 2.43 for those aged between 25--54 \[[@pone.0157791.ref006]\]. The death rate of female breast cancer patients with glycosylated hemoglobin (HbA1C) above 7% is two times higher than that of the patients with HbA1C less than 6.5% \[[@pone.0157791.ref007]\]. It was also reported that these patients with diabetes tend to have bigger tumors, regional lymph node metastasis, and distant metastasis \[[@pone.0157791.ref008]\].

Previous studies reported that the comorbidity of diabetes may be a risk factor influencing the quality of life (QOL) of patients with breast cancer. Diabetes can shorten the disease-free survival of breast cancer patients and increase the mortality of patients \[[@pone.0157791.ref009]\]. Moreover, the patients who have both diabetes and breast cancer are more sensitive to toxin and at increased risk of the adverse effects after they received chemotherapy \[[@pone.0157791.ref010]\]. Meanwhile, the patients with HbA1C above 7% have a shorter disease-free survival \[[@pone.0157791.ref007]\]. However, to the best of our knowledge, there were only a few studies investigating the influence of diabetes on QOL for patients with breast cancer. In the present study, we performed a large cross-sectional survey to explore the association between diabetes and QOL for breast cancer survivors.

Several studies find that diabetes is a factor that adversely affects the occurrence and prognosis of breast cancer \[[@pone.0157791.ref011]--[@pone.0157791.ref014]\]. Insulin is involved in the biological mechanism, and it can accelerate cell division and consequently promote cancer progression \[[@pone.0157791.ref015]--[@pone.0157791.ref017]\]. Polypeptide hormones (Leptin) can increase the disease risk of diabetes and breast cancer to some extent, and they have acceleration functions to the generation of diabetes and breast cancer \[[@pone.0157791.ref018], [@pone.0157791.ref019]\]. Fat can increase the risks of getting diabetes and breast cancer by promoting the formation of insulin resistance and activating related signal passages of insulin/IGF, besides, they are prognostic dangerous factors \[[@pone.0157791.ref020]\]. Therefore, whether combing diabetes, especially T2DM, should become one of the important factors to judge the quality of life among breast cancer survivors.

Materials and Methods {#sec006}
=====================

Study population {#sec007}
----------------

A total of 6188 female breast cancer survivors were recruited from affiliated groups of Cancer Recovery Clubs in 34 cities across China. These Clubs are non-governmental organizations aiming to improve health and QOL of patients with different kinds of cancer in China. Participants fitting the following criteria were included in this study: (1) being a primary breast cancer, (2) active treatment completed, (3) having reading ability, and (4) free from mental disorders. A written Informed Consent was obtained from every participant and the study protocols were reviewed and proved by the Ethic Committee of Public Health School of Fudan University (protocol number RB \#2013-04-0450).

Measurement of diabetes {#sec008}
-----------------------

Information on diabetes including T1DM and T2DM was collected by self-reported questionnaires and was confirmed by physicians in ≥level 2 hospitals and health records.

Measurement of Quality of Life (QOL) and the global health status (QL) {#sec009}
----------------------------------------------------------------------

The QOL was measured by the simplified Chinese version of the Quality of Life Questionnaire-Core 30(EORTC QLQ-C30) and the Quality of Life Questionnaire-Breast Cancer Module 23 (QLQ-BR23).

The EORTC QLQ-C30 consists of five functional dimensions, three symptom dimensions, a global health status (QL), and six signal items, totaling 30 items. With 23 items, QLQ-BR23 is composed of four functional dimensions and four symptom dimensions. The original scores of each dimension were transformed into standard scores with a range of 0\~100. The standard scores of functional and general health dimensions positively represented patients' QOL, meanwhile the scores of symptom dimension negatively represented QOL. Higher scores for the functional scales represent a higher level of functioning and higher scores for the symptoms represent a greater extent of symptoms. The global health status (QL) scale was used as the overall summary measure. A high score for the QL represents a high QOL. QL are 7-point questions with range = 6.The level of self-assessed QL helps in predicting survival, which is especially important among survivors to improve the QOL.

Statistical analysis {#sec010}
--------------------

Data were analyzed with the Statistical Package for the Social Sciences (SPSS) for Windows (Version19.0). Participants' characteristics and QOL were presented as percentages for categorical variables and mean ± standard deviation for continuous variables. Differences in terms of age, body mass index (BMI), years since diagnosis as well as QOL were analyzed using unpaired t-tests. Univariate analyses of covariance (ANCOVA) and multiple linear regression models were used to examine the effects of diabetes on different domains of QOL after controlling for age, BMI, education, household income, tumor characteristics (tumor size, regional lymph node metastasis, distant metastasis), and breast cancer treatment history. Statistical inferences were two-sided and *P* \<0.05 was considered as statistical significant.

Results {#sec011}
=======

The basic characteristics of study participants {#sec012}
-----------------------------------------------

As described in [Table 1](#pone.0157791.t001){ref-type="table"}, the average age of the female breast cancer survivors included in this study was 56.9±9.0 years, with 80.3% of them being over 50 years old. Their average BMI was 24.1±5.0 Kg/m^2^, and overweight or obese survivors accounted for 29.8%. Of these 6188 study participants, 614 (9.9%) survivors had been diagnosed with diabetes, 131 (3.7%) were T1DM and 483 (7.8%) were T2DM.

10.1371/journal.pone.0157791.t001

###### Characteristics of 6188 women with breast cancer, by diabetes status.

![](pone.0157791.t001){#pone.0157791.t001g}

  Characteristics                          Total   \%        Global health status (QL)   *P* value
  ---------------------------------------- ------- --------- --------------------------- -----------
  Age(years)                                                                             0.003
      \<40                                 184     3.0       67.9±20.9                   
      40-                                  1035    16.7      68.7±21.9                   
      50-                                  2807    45.4      67.4±22.9                   
      60-                                  1853    29.9      65.6±21.5                   
      70-                                  309     5.0       65.2±20.5                   
  Body Mass Index (BMI, Kg/m^2^)                             0.002                       
      \<18.5                               226     3.7       62.2±23.1                   
      18.5-                                4126    66.6      67.1±21.8                   
      25-                                  1504    24.3      67.9±23.0                   
      -30-                                 332     5.4       65.2±22.0                   
  Marital status                                                                         0.001
      Married/with partner                 5534    89.4      67.3±22.0                   
      Divorced/widowed/separated/ single   654     10.6      64.2±22.7                   
  Education                                                  0.121                       
      Middle school or vocational school   2525    40.8      66.4±22.5                   
      Junior college or above              3663    59.2      67.4±21.9                   
  Monthly personal income (RMB)                              0.210                       
      Under 2000                           2729    44.1      66.8±22.9                   
      2000--4000                           2797    45.2      66.8±21.7                   
      Over 4000                            662     10.7      68.8±20.5                   
  Primary tumor diameter (T)                                 \<0.001                     
      T0                                   448     7.3       70.3±25.3                   
      ≤20mm(T1)                            3377    54.6      67.6±21.8                   
      20mm\<T≤50mm(T2)                     1906    30.8      66.4±21.8                   
      \>50mm(T3)                           343     5.5       63.7±23.4                   
      Chest wall and skin (T4)             114     1.8       62.5±17.2                   
  Regional lymph node metastasis (N)               \<0.001                               
      N0                                   4581    74.0      67.7±21.9                   
      N1                                   1124    18.2      65.7±22.7                   
      N2                                   264     4.3       64.4±21.8                   
      N3                                   219     3.5       62.5±23.2                   
  Distant metastasis (M)                                     \<0.001                     
      M0                                   5797    93.7      67.5±22.0                   
      M1                                   391     6.3       59.7±22.9                   
  TNM staging                                                                            \<0.001
      Stage0                               366     5.9       70.1±25.7                   
      Stage1                               2701    43.6      68.0±21.6                   
      Stage2                               2214    35.8      67.1±22.0                   
      Stage3                               516     8.3       65.0±21.7                   
      Stage4                               391     6.3       59.7±22.85                  
  Diabetes                                                   0.002                       
      No                                   5574    90.1      67.3±22.0                   
      Yes                                  614     9.9       64.3±23.0                   
  Type of diabetes                                           0.008                       
      No diabetes                          5574    90.1      67.3±22.0                   
      T1DM                                 131     2.1       63.7±25.1                   
      T2DM                                 483     7.8       64.4±22.5                   

Diabetes and the global health status (QL) {#sec013}
------------------------------------------

According to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th Edition \[[@pone.0157791.ref021]\], tumor-node-metastasis (TNM) cancer staging was calculated using the indicators of tumor size (T), regional lymph node metastasis (N), and distant metastasis (M). The scoring conditions of the global health status (QL) were as follows: (1) if the tumor is larger, the scoring of QL is lower, (2) if the range of regional lymph node metastasis is larger, the scoring of QL is lower, and (3) if the distant metastasis is farther, the scoring of QL is lower.

As shown in [Table 2](#pone.0157791.t002){ref-type="table"} and [Table 3](#pone.0157791.t003){ref-type="table"}, the size of the tumor, regional lymph node metastasis, and distant metastasis were significantly associated with decreased QL. Diabetes, either T1DM or T2DM or both, significantly reduced QL. This effect of diabetes on QL is independent of tumor size, regional lymph node metastasis, distant metastasis and TNM.

10.1371/journal.pone.0157791.t002

###### The original scoring of QL on T, N, M and TNM staging.

(Original scores, Mean ± SD).
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                                      DM n = 614   T1DM n = 131   T2DM n = 483   No DM n = 5574   *P*~original~   *P*~original~   *P*~original~
  ----------------------------------- ------------ -------------- -------------- ---------------- --------------- --------------- ---------------
  Primary tumor diameter(T)                                                                                                       
      T0                              73.7±23.6    68.2±30.9      75.5±21.0      69.8±25.6        0.508           0.180           0.123
      T1                              65.1±24.3    64.2±25.3      65.4±24.0      67.8±21.6        0.009           0.039           0.061
      T2                              62.5±20.9    65.2±24.3      61.9±20.1      66.8±21.9        0.558           0.166           0.181
      T3                              61.2±20.4    65.3±8.2       60.6±21.7      64.1±23.9        0.149           0.020           0.388
      T4                              54.2±17.2    36.1±21.0      59.1±13.2      63.7±16.9        0.850           0.854           0.178
  Regional lymph node metastasis(N)                                                                                               
      N0                              65.6±21.9    65.4±24.2      65.7±21.3      67.9±21.9        0.623           0.160           0.212
      N1                              60.4±24.8    58.3±29.9      61.0±23.2      66.3±22.4        0.118           0.002           0.876
      N2                              64.5±29.7    75.0±20.4      60.1±31.4      64.4±20.8        0.000           0.982           0.000
      N3                              57.6±23.8    56.9±17.8      57.9±26.0      63.1±23.1        0.864           0.352           0.464
  Distant metastasis(M)                                                                                                           
      M0                              64.5±22.9    64.0±25.3      64.7±22.3      67.8±21.9        0.255           0.006           0.938
      M1                              61.0±24.6    60.4±23.9      61.2±25.1      59.5±22.7        0.370           0.797           0.388
  TNM staging                                                                                                                     
      Stage0                          72.6±24.2    65.8±31.5      74.7±21.5      69.7±26.0        0.560           0.199           0.145
      Stage1                          66.7±23.2    66.3±24.3      66.8±23.0      68.2±21.5        0.144           0.586           0.267
      Stage2                          62.4±21.7    63.2±25.5      62.2±20.7      67.6±22.0        0.506           0.083           0.102
      Stage3                          58.6±23.3    52.8±23.2      59.8±23.4      65.8±21.4        0.309           0.608           0.352
      Stage4                          56.0±24.6    60.4±23.9      58.2±25.1      59.5±22.7        0.370           0.797           0.388

1\. Primary tumor diameter (T): T0; ≤20mm(T1); 20mm\<T≤50mm(T2); \>50mm(T3); Tumor in any size with direct extension to chest wall and skin (T4). 2. Regional lymph node metastasis (N):N0,No regional lymph node metastasis;N1,Metastasis to movable ipsilateral axillary lymph node; N2, Metastasis to ipsilateral axillary lymph node that are fixed to one another or to other structures;N3, Metastasis to ipsilateral internal mammary lymph node. 3. Distant metastasis (M):M0, No distant metastasis; M1, Distant metastasis (Includes metastasis to ipsilateral supraclavicular lymph node). 4. TNM staing:Stage0(TisN0M0);Stage1(T1N0M0);Stage2(T0N1M0,T1N1M0,T2N0M0,T2N1M0,T3N0M0); Stage3(T0N2M0,T1N2M0,T2N2M0,T3N1M0,T3N2M0,T4N0M0,T4N1M0,T4N2M0,TiN3M0);Stage4(TiNiM1). 5. Original scores, Mean ± Standard Deviation

10.1371/journal.pone.0157791.t003

###### The adjusted scoring of QL on T, N, M and TNM staging.

(Adjusted scores, Mean ±SE).
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                                      DM n = 614   T1DM n = 131   T2DM n = 483   No DM n = 5574   *P*~adjusted~DM vs. No DM   *P*~adjusted~ T1DM vs. No DM   *P*~adjusted~ T2DM vs. No DM
  ----------------------------------- ------------ -------------- -------------- ---------------- --------------------------- ------------------------------ ------------------------------
  Primary tumor diameter(T)                                                                                                                                  
      T0                              74.5±4.6     71.7±8.3       77.0±4.9       71.1±1.8         0.493                       0.339                          0.256
      T1                              64.6±1.4     65.2±2.2       64.7±1.5       68.3±0.4         0.009                       0.143                          0.023
      T2                              62.4±1.7     64.6±3.9       61.9±1.8       67.0±0.6         0.009                       0.531                          0.008
      T3                              61.9±3.5     65.5±9.8       61.3±3.8       63.5±1.5         0.694                       0.845                          0.601
      T4                              52.3±4.9     42.3±0.2       56.0±5.7       64.1±1.8         0.031                       0.043                          0.180
  Regional lymph node metastasis(N)                                                                                                                          
      N0                              64.9±1.1     64.2±2.5       65.0±1.3       68.4±0.4         0.003                       0.099                          0.011
      N1                              60.7±2.3     58.6±4.6       61.5±2.7       66.5±0.7         0.018                       0.093                          0.071
      N2                              64.2±4.4     74.7±10.0      61.7±4.9       65.0±1.5         0.848                       0.294                          0.510
      N3                              58.2±4.9     58.6±9.3       58.6±5.7       61.9±1.7         0.476                       0.721                          0.583
  Distant metastasis(M)                                                                                                                                      
      M0                              63.9±1.0     62.9±2.2       64.2±1.1       68.2±0.3         0.000                       0.017                          0.001
      M1                              61.9±3.6     62.5±7.9       61.9±4.0       59.8±1.3         0.569                       0.746                          0.622
  TNM staging                                                                                                                                                
      Stage0                          72.7±5.1     45.0±15.3      76.3±5.4       71.1±2.0         0.764                       0.108                          0.324
      Stage1                          66.0±1.5     66.4±3.2       65.9±1.7       68.6±0.5         0.108                       0.481                          0.134
      Stage2                          62.1±1.5     62.6±3.3       62.1±1.7       67.9±0.5         0.000                       0.088                          0.001
      Stage3                          58.5±3.0     55.1±7.2       59.3±3.3       65.9±1.1         0.024                       0.140                          0.061
      Stage4                          61.9±3.6     62.5±7.9       61.9±4.1       59.8±1.3         0.569                       0.746                          0.622

1.Primary tumor diameter (T): T0; ≤20mm(T1); 20mm\<T≤50mm(T2); \>50mm(T3); Tumor in any size with direct extension to chest wall and skin (T4). 2.Regional lymph node metastasis(N):N0,No regional lymph node metastasis;N1,Metastasis to movable ipsilateral axillary lymph node; N2, Metastasis to ipsilateral axillary lymph node that are fixed to one another or to other structures;N3, Metastasis to ipsilateral internal mammary lymph node. 3. Distant metastasis (M):M0, No distant metastasis; M1, Distant metastasis (Includes metastasis to ipsilateral supraclavicular lymph node). 4. TNM staing:Stage0(TisN0M0);Stage1(T1N0M0);Stage2(T0N1M0,T1N1M0,T2N0M0,T2N1M0,T3N0M0); Stage3(T0N2M0,T1N2M0,T2N2M0,T3N1M0,T3N2M0,T4N0M0,T4N1M0,T4N2M0,TiN3M0);Stage4(TiNiM1) 5.Adjusted factors: Age, Marital status, BMI, Education, Personal income, Time after diagnosis, Treatment and Other chronic diseases (hypertension, hyperlipidemia, hyperuricemia, coronary heart disease, respiratory disease, stroke, musculoskeletal disease). 6. Adjusted scores, Mean ± Standard Error

Diabetes and QOL for breast cancer patients {#sec014}
-------------------------------------------

[Table 4](#pone.0157791.t004){ref-type="table"} presents the association between diabetes and QOL for breast cancer patients. After adjusting for social-demography, diagnosis and treatment of the tumor, tumor stage and other chronic diseases, diabetic patients got significantly lower EORTC QLQ-C30 scores in terms of functional dimensions, including physical functioning (PF), role functioning (RF), emotional functioning (EF) and global health status (QL) than those without diabetes. The scorings of diabetic patients in symptom dimensions, including fatigue (FA), nausea and vomiting (NV), pain (PA), dyspnoea (DY), insomnia (SL), constipation (CO) and diarrhoea (DI), as well as economic difficulties were all higher than the scorings of survivors without diabetes. The scorings of T1DM in functional dimensions were all lower than the scorings of survivors who do not have T1DM, in symptom dimensions except for AP and CO, and the scorings of T1DM patients in symptom dimension were all higher than the scorings of survivors without T1DM, and the scorings in CF, EF, QL, FA, NV, DY, SL, CO and DI all have statistical significance. The scorings of breast cancer patients who also have T2DM in functional dimension were all lower than the scorings of survivors who do not have T2DM, in symptom dimensions except for FA, CO and DI, and the scorings of T2DM patients in symptom dimension were all higher than the scorings of survivors who do not have T2DM, and the scorings in PF, RF, QL, FA, PA, DY, SL, AP, CO and FI all have statistical significance.

10.1371/journal.pone.0157791.t004

###### The association between diabetes mellitus and original scores of QOL among breast cancer survivors.

(Original scores, (Mean~DMi~-Mean ~No\ DM~)(Mean~DMi~±SD)).
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                                   DM,n = 614               T1DM,n = 131            T2DM,n = 483
  ------------------------ ------- ------------------------ ----------------------- ------------------------
  EORTC QLQ-C30                                                                     
  Global health status     QL      -3.0(64.3±23.1) \*\*     -1.3(65.7±24.1)         -2.8(64.4±22.5) \* \*
  Physical functioning     PF      -2.6(82.4±14.9) \*\*\*   -2.4(82.4±15.2) \*      -2.5(82.4±15.5) \*\*\*
  Role functioning         RF      -1.3(89.3±19.1)          -1.1(89.4±18.7)         -1.2(89.4±18.4)
  Cognitive functioning    CF      -1.8(79.5±18.7) \*       -3.6(77.6±18.8) \*\*    -0.7(80.5±17.8)
  Emotional functioning    EF      -1.7(83.2±18.0) \*       -3.3(81.5±19.7) \*\*    -1.0(83.8±17.5)
  Social functioning       SF      -1.4(80.9±21.9)          -2.3(79.9±23)           -1.7(80.6±22.6)
  Fatigue                  FA      2.2(26.9±18.8) \*\*      2.2(27.0±19.2) \*       1.6(26.4±18.0)
  Nausea and vomiting      NV      0.8(3.5±10.8) \*         1.8(4.5±11.8) \*\*      -0.2(2.6±8.4)
  Pain                     PA      2.6(17.7±18.3) \*\*\*    3.7(18.9±18.8) \*\*     2.0(17.3±18.1) \*\*
  Dyspnoea                 DY      4.4(16.9±22.1) \*\*\*    4.5(17.3±21.6) \*\*\*   3.8(16.4±21.6) \*\*\*
  Insomnia                 SL      3.9(22.5±25.0) \*\*\*    4.2(23.1±24.8) \*\*     3.1(21.9±25.9) \*\*
  Appetite loss            AP      1.0(7.6±15.7)            0.9(7.5±16.3)           0.9(7.6±16.5)
  Constipation             CO      3.3(12.2±20.7) \*\*\*    0.7(9.9±19.4)           3.1(12.0±20.5) \*\*\*
  Diarrhoea                DI      2.7(9.7±18.4) \*\*\*     4.0(11.1±18.6) \*\*\*   1.8(8.9±17.9) \*
  Financial difficulties   FI      3.8(31.0±32.3) \*\*      4.7(32.1±32.5)          4.3(31.6±33.1) \*\*
  QLQ-BR23                                                                          
  Body image               BRBI    -2.9(64.1±25.8) \*\*     -2.7(64.1±25.5) \*      -2.3(64.6±25.7) \*
  Sexual functioning       BRSEF   -2.9(95.0±13.0) \*\*\*   -2.1(94.3±13.1)         -3.4(95.4±12.1) \*\*\*
  Sexual enjoyment         BRSEE   -4.4(95.1±13.6) \*\*\*   -3.5(94.6±13.2)         -4.9(95.7±12.5) \*\*\*
  Future perspective       BRFU    -4.9(58.0±32.9) \*\*\*   -3.2(59.3±33.1)         -4.9(57.9±33.5) \*\*
  Side effects             BRST    3.7(19.4±13.1) \*\*\*    3.9(19.8±13.5) \*\*\*   3.4(19.2C13.4) \*\*\*
  Breast symptoms          BRBS    4.5(20.8±20.8) \*\*\*    5.4(21.9±20.2) \*\*\*   3.9(20.3±20.8) \*\*\*
  Arm symptoms             BRAS    3.6(25.5±22.2) \*\*\*    3.9(26.0±21.2) \*       3.5(25.5±22.8) \*\*\*
  Upset by hair loss       BRHL    3.3(21.5±27.3) \*\*      2.7(21.1±25.9)          3.4(21.7±28.1) \*\*

1\. DM, contained T1DM and T2DM; 2.Original scores, (Mean~DMi~-Mean ~No\ DM~)(Mean~DMi~ ±SD): The difference value between mean score of quality of life instrument with having diabetes and having no it. (mean score of quality of life instrument with having diabetes). 3.\* *P* \<0.05, \*\* *P* \<0.01, \*\*\* *P* \<0.001.

As shown in [Table 5](#pone.0157791.t005){ref-type="table"}, the scorings of diabetic patients in two QLQ-BR23 functional dimensions, including body image (BRBI) and future perspective (BRFU) were significantly lower than the scorings of survivors without diabetes. The scorings of diabetic patients in 4 symptom dimensions, including side effects (BRST), breast symptoms (BRBS), arm symptoms (BRAS) and upset by hair loss (BRHL) were higher than the scorings of survivors without these 4 symptoms, and all the scorings have statistical significance. The scorings of breast cancer survivors combined with T1DM in functional dimensions BRSEF and BRSEE were all lower than related scorings of survivors without T1DM. The scorings of T1DM patients in symptom dimensions were all higher than the scorings of survivors without T1DM, and the scoring difference in BRST, BRBS and BRHL has statistical significance. Except for functional dimension BRBI, the scorings of breast cancer survivors combined with T2DM in other functional dimension were all lower than the scorings of survivors who do not have T2DM. The scorings of T2DM patients in symptom dimensions were all higher than the scorings of survivors without T2DM, and the scorings of symptom dimensions and functional dimensions all have statistical significance.

10.1371/journal.pone.0157791.t005

###### The association between diabetes mellitus and adjusted scores of QOL among breast cancer survivors.

(Adjusted scores,(Mean~DMi~-Mean ~No\ DM~) (Mean~DMi~±SE))
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                                   DM,n = 614              T1DM,n = 131          T2DM,n = 483
  ------------------------ ------- ----------------------- --------------------- -----------------------
  EORTC QLQ-C30                                                                  
  Global health status     QL      -2.1(65.2±1.1) \*\*     -0.2(65.6±1.8) \*     -3.3(67.4±1.3) \*
  Physical functioning     PF      -2.9(82.3±0.7) \*\*\*   -1.4(82.3±1.1)        -1.4(82.3±0.8) \*\*\*
  Role functioning         RF      -1.8(89.0±0.9) \*       -0.6(89.1±1.4)        -1.0(89.0±1.0) \*
  Cognitive functioning    CF      -2.0(79.2±0.9)          -2.6(78.4±1.5) \*     -2.4(80.9±1.0)
  Emotional functioning    EF      -2.9(82.0±0.9) \*\*     -3.0(81.2±1.4)\*      -0.4(82.9±1.0)
  Social functioning       SF      -1.9(80.4±1.1)          -0.7(80.5±1.8)        -3.7(79.0±1.2)
  Fatigue                  FA      2.8(27.1±1.0) \*\*      1.2(27.0±1.6) \*      -1.0(25.9±1.1) \*
  Nausea and vomiting      NV      1.1(3.9±0.5) \*         1.1(4.2±0.8) \*\*\*   1.0(2.6±0.5)
  Pain                     PA      2.3(17.5±0.9) \*\*      0.9(17.4±1.4)         1.6(17.8±1.0) \*\*
  Dyspnoea                 DY      5.0(17.3±1.0) \*\*\*    2.2(17.2±1.6) \*\*    0.7(16.4±1.1) \*\*\*
  Insomnia                 SL      4.5(23.2±1.2) \*\*\*    3.2(23.7±1.9) \*      0.2(22.2±1.3) \*\*
  Appetite loss            AP      1.0(7.7±0.8) \*\*       -1.5(6.7±1.3)         0.6(7.8±0.9) \*\*
  Constipation             CO      1.4(10.4±0.9) \*\*      -1.7(9.2±1.5) \*      -1.7(9.2±1.0) \*\*
  Diarrhoea                DI      2.9(10.1±0.8) \*\*      2.9(10.8±1.3)\*\*\*   -1.9(8.5±0.9)
  Financial difficulties   FI      4.7(31.5±1.5) \*\*      0.5(30.6±2.4)         6.6(33.7±1.7) \*\*\*
  QLQ-BR23                                                                       
  Body image               BRBI    -3.0(64.1±1.3)\*\*      0.3(65.0±2.1)         0.0(64.8±1.5) \*
  Sexual functioning       BRSEF   -0.8(93.1±0.7)          -1.0(92.4±1.2)        -2.9(94.3±0.8) \*
  Sexual enjoyment         BRSEE   -1.7(92.8±0.9)          -0.5(92.1±1.4)        -3.3(94.0±1.0)\*
  Future perspective       BRFU    -3.0(60.2±1.6) \*\*     2.9(62.4±2.7)         -1.7(60.1±1.8) \*\*
  Side effects             BRST    4.0(20.0±0.7) \*\*\*    2.6(20.3±1.1)\*\*     1.6(19.8±0.7) \*\*\*
  Breast symptoms          BRBS    5.3(21.6±0.9) \*\*\*    3.3(21.9±1.4)\*\*\*   0.6(20.6±1.0) \*\*\*
  Arm symptoms             BRAS    3.7(25.6±1.0) \*\*      2.3(25.8±1.7)         2.5(25.9±1.2) \*\*
  Upset by hair loss       BRHL    4.3(22.0±1.3) \*\*      3.1(22.5±2.1)         1.7(21.7±1.5) \*

Notes: 1. DM, contained T1DM and T2DM; 2.Adjusted factors: Age, Marital status, BMI, Education, Personal income, Time after diagnosis, Treatment, Tumor staging and Other chronic disease (hypertension, hyperlipidemia, hyperuricemia, coronary heart disease, respiratory disease, stroke, musculoskeletal disease). 3.Adjusted scores,(Mean~DMi~-Mean ~No\ DM~)(Mean~DMi~±SE): The difference value between mean score of quality of life instrument with having diabetes and having no it. (mean score of quality of life instrument with having diabetes). 4. \* *P* \<0.05, \*\* *P* \<0.01, \*\*\* *P* \<0.001.

Discussion {#sec015}
==========

WHO highlights that comprehensive measures are needed to improve the QOL of chronic disease patients \[[@pone.0157791.ref022]\]. Diabetes and breast cancer can not only threaten the health and mortality rate of patients, but also affects the QOL of patients \[[@pone.0157791.ref023]\]. Survival alone is not sufficient for breast cancer survivors, who also want to live a life without health concerns. QOL has also been shown to be a significant prognostic factor for mortality and cancer recurrence \[[@pone.0157791.ref024], [@pone.0157791.ref025]\]. In the current investigation, we carried out a relatively large cross-sectional study to explore the association between comorbidity of diabetes mellitus and QOL of breast cancer survivors. What was found in this study indicated that the comorbidity of diabetes significantly affects almost all dimensions of QOL of breast cancer survivors. Therefore, control and treatment of diabetes (especially T2DM) may improve the QOL of breast cancer survivors, including their general health condition and standard of life.

Diabetes may decrease cancer patients' QOL in various ways. Diabetes could promote more rapid growth of tumors through metabolic factors such as hyperglycemia, insulin resistance, and hyperinsulinemia \[[@pone.0157791.ref026]--[@pone.0157791.ref028]\]. Hyperinsulinemia in T2DM induced the expression and increased the binding capacity of Estrogen Receptor (ER) \[[@pone.0157791.ref029]\]. Diabetes is also an adverse factor that can affect the prognostic life quality of breast cancer patients \[[@pone.0157791.ref030]\]. Diabetes may also exert indirect effects on breast cancer because of the associated end-organ damage that may affect screening and treatment options, enhance treatment toxicity, and lead to worse outcomes \[[@pone.0157791.ref031]\].

The participants of this study came from Cancer Recovery Clubs in 34 cities all over China, and they may have good representativeness of the breast cancer survivors in China. It should be kept in mind that severe patients were not included, as well as the dead registered members after tumor diagnosis. Information on the disease was collected by self-reports, and some recall bias may exist.

Despite the fact that a strong association between comorbidity of diabetes and QOL of breast cancer survivors was found in our study, due to the inherent limitation of cross-sectional study design, we cannot determine specific causal relationships. There are the studies that indicate the treatment for diabetes, for instance, the long-acting insulin analog glargine may be responsible for the association with the risk of cancer \[[@pone.0157791.ref032], [@pone.0157791.ref033]\]. Meanwhile, the chemotherapy for the treatment of breast cancer causes the increase of blood glucose \[[@pone.0157791.ref010]\]. In addition, we need to collect more clinical data (including prospective cohort studies of mass samples) and molecular biological evidence (for example, the test of insulin-like growth factor receptor in breast cancer samples) \[[@pone.0157791.ref034]\]. Further investigations are warranted to explore the mechanism of this effect.

Conclusion {#sec016}
==========

This study provides strong evidence that comorbidity of diabetes, especially T2DM, aggravates the QOL of breast cancer survivors. Thus, the prevention and proper treatment of comorbidity of diabetes are required to improve the QOL of diabetes and breast cancer survivors.
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